1. Home
  2. BRT vs TTRX Comparison

BRT vs TTRX Comparison

Compare BRT & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BRT Apartments Corp. (MD)

BRT

BRT Apartments Corp. (MD)

N/A

Current Price

$14.08

Market Cap

271.2M

Sector

Real Estate

ML Signal

N/A

Logo Turn Therapeutics Inc.

TTRX

Turn Therapeutics Inc.

N/A

Current Price

$14.25

Market Cap

298.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BRT
TTRX
Founded
1972
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
271.2M
298.8M
IPO Year
1994
2025

Fundamental Metrics

Financial Performance
Metric
BRT
TTRX
Price
$14.08
$14.25
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$19.75
$8.00
AVG Volume (30 Days)
31.3K
69.8K
Earning Date
05-08-2026
05-31-2026
Dividend Yield
7.03%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$97,028,000.00
N/A
Revenue This Year
$3.82
N/A
Revenue Next Year
$5.35
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.46
N/A
52 Week Low
$13.18
$2.57
52 Week High
$16.69
$14.39

Technical Indicators

Market Signals
Indicator
BRT
TTRX
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
BRT
TTRX

About BRT BRT Apartments Corp. (MD)

BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

Share on Social Networks: